COPERNICUS: A Pragmatic Phase 2b Study of First-Line (1L) Subcutaneous (SC) Amivantamab (Ami) + Lazertinib (Laz) With Supportive Care in EGFR-Mutated Advanced NSCLC: Early Safety Results

The COPERNICUS study evaluates the safety and patient characteristics of a subcutaneous treatment regimen combined with targeted therapies and proactive side-effect management for advanced lung cancer. By utilizing a pragmatic design that simplifies monitoring and reduces clinic visit frequency, the trial reflects an accessible approach to patient care modeled after local practices. Early findings indicate that this combination approach lowers the occurrence of severe adverse events and administration-related reactions compared to historical intravenous delivery methods.